NCT06719570 A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055) Status COMPLETED Phase PHASE1
NCT06619678 A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016) Status COMPLETED Phase PHASE1
NCT05130086 A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) Status WITHDRAWN Phase PHASE2
NCT05115838 Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043) Status WITHDRAWN Phase PHASE2
NCT04644029 Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) Status TERMINATED Phase PHASE3
NCT04564547 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] Status COMPLETED Phase PHASE2
NCT04515641 Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030) Status COMPLETED Phase PHASE1
NCT04303156 Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026) Status COMPLETED Phase PHASE1
NCT04003103 Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) Status COMPLETED Phase PHASE2
NCT03272347 Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) Status COMPLETED Phase PHASE2